Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: Results of a european, multicenter, randomized, controlled trial

Oncologist

Volumn 15, Issue 9, 2010, Pages 935-943

  Pronzato, Paolo ^a   Cortesi, Enrico ^b   van der Rijt, Carin C ^c   Bols, Alain ^d   Moreno Nogueira, José A ^e   de Oliveira, Carlos Freire ^f   Barrett Lee, Peter ^g   Ostler, Peter J ^h   Rosso, Ricardo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d General Hospital St Jan   (Belgium)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^g VELINDRE CANCER CENTRE   (United Kingdom)

^h MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Anemia; Breast cancer; Erythropoietin; Fatigue; Hemoglobin; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ABDOMINAL DISEASE; ADULT; AGED; ANEMIA; ANXIETY; AREA UNDER THE CURVE; ARTHROPATHY; ARTICLE; BLOOD TRANSFUSION; BONE DISEASE; BONE MARROW DEPRESSION; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM DISEASE; EARLY INTERVENTION; ERYTHROCYTE COUNT; EUROPE; EYE DISEASE; FATIGUE; FEMALE; HEAD INJURY; HUMAN; LARGE INTESTINE DISEASE; LEUKOCYTE COUNT; LUNG DISEASE; MAJOR CLINICAL STUDY; MOTOR NEUROPATHY; MUCOSAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROSIS; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHARYNX DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SENSORY NEUROPATHY; SIDE EFFECT; SKIN DISEASE; SMALL INTESTINE DISEASE; STOMACH DISEASE; THORAX DISEASE; TREATMENT OUTCOME; VEIN THROMBOSIS;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; BREAST NEOPLASMS; EPOETIN ALFA; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 77957767662     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0279     Document Type: Article

References (19)

1. American Cancer Society. Overview: Breast Cancer. Available at http:// www.cancer.org, accessed November 9, 2009.
2. Ludwig H, Van Belle S, Barrett-Lee P et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-2306.
3. Ludwig H, Aapro M, Bokemeyer C et al. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: Findings from the Anaemia Cancer Treatment (ACT) study. Eur J Cancer 2009;45:1603-1615.
4. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993; 29A(suppl 2):S2-S8.
5. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebocontrolled trial. J Clin Oncol 2001;19:2865-2874.
6. Witzig TE, Silberstein PT, Loprinzi CL et al. Phase III, randomized, double- blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-2617.
7. Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218 -1234.
8. Demetri GD, Kris M, Wade J et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-3425.
9. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
10. Cella D, Eton DT, Lai JS et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Func-tional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24:547-561.
11. Chang J, Couture F, Young S et al. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005;23:2597-2605.
12. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double- blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
13. Leyland-Jones B, Semiglazov V, Pawlicki M. et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005;23:5960 -5972.
14. Overgaard J, Hoff C, Sand Hansen H et al. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): The Danish Head and Neck Cancer Group (DAHANCA 10) randomized trial. Eur J Cancer 2007;5(suppl):7.
15. Moebus V, Lueck H, Thomssen C et al. The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancerpatients (pts) treated with dose-dense sequential chemotherapy: Mature results of an AGO phase III study (ETC trial) [abstract 569]. J Clin Oncol 2007;25(20 suppl):20s.
16. Aapro M, Leonard RC, Barnadas A et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: Results of the Breast Cancer- Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol 2008;26:592-598.
17. Untch M, Fasching PA, Bauerfeind I et al. PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin/cyclophosphamide followed by paclitaxel {+/-} darbepoetin alfa in primary breast cancer: A preplanned interim analysis of efficacy at surgery [abstract 517]. J Clin Oncol 2008;26(10 suppl):10s.
18. Cella D. The effects of anemia and anemia treatment on the quality of life of people with cancer. Oncology (Williston Park) 2002;16(suppl 10):125-132.
19. Cella D, Kallich J, McDermott A et al. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: Results from five randomized clinical trials. Ann Oncol 2004;15:979-986.